Ascendis Pharma A/S (NASDAQ:ASND) Price Target Cut to $180.00

Ascendis Pharma A/S (NASDAQ:ASND – Get Rating) had its target price dropped by equities researchers at Cantor Fitzgerald from $230.00 to $180.00 in a research report issued to clients and investors on Thursday, The Fly reports. Cantor Fitzgerald’s target price would suggest a potential upside of 130.53% from the stock’s current price.

ASND has been the subject of several other reports. Oppenheimer decreased their target price on shares of Ascendis Pharma A/S from $166.00 to $154.00 in a report on Thursday. Citigroup decreased their target price on shares of Ascendis Pharma A/S from $187.00 to $158.00 in a report on Thursday. Zacks Investment Research cut shares of Ascendis Pharma A/S from a “buy” rating to a “hold” rating in a report on Monday, January 17th. Wedbush reaffirmed an “outperform” rating on shares of Ascendis Pharma A/S in a report on Monday, March 28th. Finally, Credit Suisse Group decreased their target price on shares of Ascendis Pharma A/S from $194.00 to $123.00 in a report on Thursday. One research analyst has rated the stock with a sell rating, two have issued a hold rating and eleven have issued a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $163.58.

NASDAQ:ASND opened at $78.08 on Thursday. Ascendis Pharma A/S has a one year low of $75.70 and a one year high of $178.71. The company’s 50-day simple moving average is $106.85 and its 200 day simple moving average is $123.42. The firm has a market capitalization of $4.45 billion, a P/E ratio of -9.42 and a beta of 0.86.

Ascendis Pharma A/S (NASDAQ:ASND – Get Rating) last posted its quarterly earnings data on Wednesday, May 11th. The biotechnology company reported ($2.21) EPS for the quarter, topping the consensus estimate of ($2.25) by $0.04. Ascendis Pharma A/S had a negative net margin of 5,015.63% and a negative return on equity of 45.19%. During the same quarter last year, the company earned ($1.41) EPS. As a group, analysts anticipate that Ascendis Pharma A/S will post -8.95 earnings per share for the current year.

A number of hedge funds have recently made changes to their positions in ASND. Wells Fargo & Company MN increased its holdings in Ascendis Pharma A/S by 37.7% during the second quarter. Wells Fargo & Company MN now owns 11,259 shares of the biotechnology company’s stock valued at $1,482,000 after buying an additional 3,082 shares during the last quarter. Morgan Stanley increased its holdings in Ascendis Pharma A/S by 179.8% during the second quarter. Morgan Stanley now owns 78,350 shares of the biotechnology company’s stock valued at $10,307,000 after buying an additional 50,343 shares during the last quarter. SG Americas Securities LLC increased its holdings in Ascendis Pharma A/S by 28.8% during the third quarter. SG Americas Securities LLC now owns 3,254 shares of the biotechnology company’s stock valued at $519,000 after buying an additional 727 shares during the last quarter. Russell Investments Group Ltd. boosted its position in shares of Ascendis Pharma A/S by 25.8% in the third quarter. Russell Investments Group Ltd. now owns 25,455 shares of the biotechnology company’s stock worth $4,056,000 after purchasing an additional 5,214 shares during the period. Finally, BlackRock Inc. boosted its position in shares of Ascendis Pharma A/S by 1.0% in the third quarter. BlackRock Inc. now owns 339,076 shares of the biotechnology company’s stock worth $54,046,000 after purchasing an additional 3,315 shares during the period.

About Ascendis Pharma A/S (Get Rating)

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia.

Featured Stories